BIO.BE is the Belgian federation of companies active in life sciences and biotechnologies. It is part of essenscia, the Belgian federation for chemistry and life sciences industries.

In its advocacy role, represents the interests of its members as regards to legislation and standards at various policy levels (Belgium, EU, OECD).
In its communication role, the federation promotes the excellence of its members to deliver innovative products, services and technologies for a better life for today and for the future.

The mission of is to foster a supportive environment and a stable legal framework in line with the trend for innovation, an essential factor for:
  • the economic sustainability and employment growth in the sector;
  • the capability of this sector to answer major societal challenges. can rely on synergies within the essenscia group, including with the regional branches essenscia wallonia, essenscia brussels and essenscia vlaanderen as well as with the products’ sectors such as It has also access to the expertise of its extensive network of partners. is, for example, the Belgian national association contact point for EuropaBio, the European association for bioindustries, and is also member of ICBA, the International Council of Biotechnology Associations jointly created by BIO and EuropaBio.

Discover the memorandum of

Biotech meets digital - 21 March 2019 essenscia and Agoria join forces to accelerate the digitalization of biotechnology companies in Belgium.

Click here to read the press release 


Annual event - Scale up! It’s time to grow for biotech companies 23 October 2018

Yes, Life sciences and biotech companies are at the top in Belgium.
Yes, they are innovative and they find capital and investors.
But it does not come from a magic wand !

What are the challenges biotech companies face in their scale-up process?

Find it out at our event “Scale up! It’s time to grow for biotech companies”.

Provisional agenda :

• Introduction
- Tineke Van hooland (AbbVie), Chairwoman of

• DARE: be ambitious, take risks
- John Tchelingerian, CEO Promethera BioSciences

FINANCE: importance of an industrial board and -investors
- Jean Stéphenne, Chairman or Board Member of different life sciences companies (Bone Therapeutics, OncoDNA, BePharBel…)
- Christina Takke, co-founder and Managing Director at

• WORK: good teams are key
Annelies Missotten, Vice President HR, Galapagos
- Pauline Rambaud, Senior Consultant, GenSearch

• Conclusion: lessons learned by success or failure
- Koen Segers, Director Healthcare Practice Deloitte

Each presentation will be followed by a debate led by F. Druck, Secretary General at and commented by Prof. B. Surlemont (HEC Liège)

Context to these three topics

The scale-up phase is a challenging time for Biotech and Life Sciences spin-offs and start-ups. On their ways to become a company as such, they already passed different crash-tests successfully in their early development phase such as technology assessment with key partners, effectiveness of the business model, growing sales, confidence of investors, etc. It is now time to grow and to create economic and social added values.


 Register now

Annual event 26 September 2017 - "Life sciences and biotechnologies in Belgium - Growth! Growth! Growth

Board members

Name Company
Tineke Van hooland ABBVIE (Chair)
 Carrez Dirk  Clever Consult
 Gordon-Beresford Roland  Novadip
 Neutens Tijs  Amgen
 Janssens Elke  Nautadutilh
 Martens Marc  Bird & Bird
 Noirhomme Cristelle  GlaxoSmithKline Vaccines
Pot Geoffrey         Shire
Schelfhout Bart  Sanofi
Van Aarle Ingrid SES Vanderhave
Van Loo Albert Genencor International
Vanwijnsberghe Vincent Novartis
Druck Frédéric
Meekers Sylvie